ACKR1 and Plasmodium vivax malaria: Indeed, evidence that P. vivax merozoites invade DARC+ DN erythroblasts suggests that the leading vaccine candidate targeting the PvDBPII-binding domain of PvDBP in P. vivax merozoites44,45,46 could be used to prevent vivax malaria in both DP and DN populations.